Octreotide
(Somatostatin)Phase 1Small molecule
Johnson & JohnsonSomatostatin is used to treat certain hormone-producing tumors and control severe diarrhea and flushing caused by specific cancers. It works by reducing the amount of hormones your body produces that cause these symptoms.[1] Octreotide is currently being investigated across 7 indications[3], with its most advanced program in Phase 1.[1]
Octreotide is one of 73 small molecule programs targeting Liver Transplant. It is currently in Phase 1.
7
Indications
35
Total Trials
6
Active Trials
72
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
95 competitors in Liver Transplant
#DrugCompanyPhaseTrials
1Giapreza
LLa Jolla Pharmaceutical Company
Phase 3
Prothrombin Complex Concentrate
CSL BehringPhase 3
Darbepoetin
BayerPhase 3
Octreotide
Johnson & JohnsonPhase 1
Tacrolimus Pill
EEdward Geissler
Phase 3
Lenvima
EisaiPreclinical
Beyfortus
BeiGenePreclinical
Prostigmin
Merck & Co.Preclinical
Myfortic
NovartisPreclinical
Cyklokapron
JJ Molner
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metabolism3 trials
Hypoglycemia2 trials
Liver Transplant2 trials
Hepatocellular Carcinoma2 trials
25 more indications
Gastric Varices1 trial
Insulin Secretion1 trial
Bleeding1 trial
Liver Resection1 trial
Gastrointestinal1 trial
Metabolic Consequences of Gastrointestinal Surgery
Terminated·—·N/A·NCT02836353·81 enrolled
Acute Variceal Bleeding1 trial
Postoperative Pancreatic Fistula1 trial
Acute Kidney Injury1 trial
Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding
Completed·—·Phase 4·NCT04358016·54 enrolled
Pancreatitis1 trial
Gastrointestinal hemorrhage1 trial
Prostate Cancer1 trial
Gastric Cancer1 trial
Gallbladder Carcinoma1 trial
Small Bowel Obstruction1 trial
Pancreaticoduodenectomy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Somatostatin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Somatostatin Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company